Fludara

(Fludarabine Phosphate)

Phase 3Small molecule

Fludarabine phosphate is used to treat certain blood cancers, particularly chronic lymphocytic leukemia (CLL), by killing cancer cells and weakening the immune system in patients who haven't responded well to other treatments.[1] Fludara is currently being investigated across 37 indications[3], with its most advanced program in Phase 3.[1]

Fludara is one of 674 small molecule programs targeting Colorectal Cancer. It is currently in Phase 3.

Indications

386

Total Trials

Active Trials

673

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Hematological MalignanciesCompleted

PreventionTerminated

Epidermolysis BullosaActive, not recruiting

Acute Lymphoblastic Leukemia in RemissionRecruiting

Recurrent B-Cell Non-Hodgkin LymphomaActive, not recruiting

Solid TumorActive, not recruiting

Recurrent Diffuse Large B-Cell LymphomaRecruiting

B Acute Lymphoblastic LeukemiaActive, not recruiting

Immune ThrombocytopeniaNot yet recruiting

Colorectal CancerPhase 1

Active, not recruiting

Hematological MalignanciesPhase 2

Completed

PreventionPhase 2

Terminated

Epidermolysis BullosaPreclinical

Active, not recruiting

Acute Lymphoblastic Leukemia in RemissionPreclinical

Recruiting

Recurrent B-Cell Non-Hodgkin LymphomaPreclinical

Active, not recruiting

Solid TumorPreclinical

Active, not recruiting

Recurrent Diffuse Large B-Cell LymphomaPhase 1

Recruiting

B Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Immune ThrombocytopeniaPhase 2

Not yet recruiting

Showing 10 of 37 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

22 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Melanoma

NCT04119024

N/AActive, not recruiting

Hematopoietic Stem Cell Transplant

NCT01652092

Q2 2027

Phase 1/2Active, not recruiting

Graft Versus Host Disease

NCT03192397

Q3 2027

Phase 2Recruiting

Prevention

NCT06550141

Q4 2027

Phase 2Active, not recruiting

Myelodysplastic Syndrome

NCT02250937

Phase 2Active, not recruiting

Advanced Malignancies

NCT01697527

Clinical

Trials by Indication[1]

Stem Cell Transplant26 trials

Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers

Completed·UUniversity of California, Davis·Phase 2·NCT00619645·8 enrolled

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recruiting·UUniversity of Chicago·Phase 1·NCT02333162·30 enrolled

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No longer available·BBarbara Ann Karmanos Cancer Institute··NCT00423826

Show 23 more trials

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00027560·51 enrolled

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT04776850

Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00346359·40 enrolled

Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005941

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·YYale University·Phase 1·NCT00104975·20 enrolled

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00112593·5 enrolled

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00053196·82 enrolled

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00448201·71 enrolled

Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

Completed·—·Phase 1·NCT00376480·19 enrolled

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Completed·—·Phase 2·NCT00627666·52 enrolled

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01823198·63 enrolled

Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00919503·98 enrolled

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00118352·12 enrolled

Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00075478·87 enrolled

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

Completed·UUniversity of California, San Francisco·N/A·NCT00296023·25 enrolled

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Terminated·—·Phase 1·NCT00800150·6 enrolled

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Completed·NNorthside Hospital, Inc.·Phase 2·NCT00787761·24 enrolled

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Completed·UUniversity of California, San Francisco·Phase 2·NCT00301834·35 enrolled

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT01300572·16 enrolled

Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00392782·24 enrolled

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01056614·23 enrolled

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Terminated·NNorthside Hospital, Inc.·Phase 2·NCT00818961·36 enrolled

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00303667·50 enrolled

Chronic Lymphocytic Leukemia20 trials

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01027000·68 enrolled

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT00096018·43 enrolled

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00625729·6 enrolled

Show 17 more trials

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002838·13 enrolled

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00068315·18 enrolled

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00602459·418 enrolled

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Completed·GGerman CLL Study Group·Phase 2·NCT00278213·17 enrolled

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed·GGenta Incorporated·Phase 3·NCT00024440

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00612612·28 enrolled

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

Completed· Bayer logo

Bayer·Phase 2·NCT00086775

Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00049075·128 enrolled

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Active, not recruiting·—·Phase 1·NCT02153580·37 enrolled

Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017108

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00104858·66 enrolled

A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

Completed· Sanofi logo

Sanofi·Phase 4·NCT00220311·10 enrolled

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003659·39 enrolled

Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT00045513

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Completed·CCancer Research UK·Phase 2·NCT00337246·56 enrolled

Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00425802·61 enrolled

Lymphoma14 trials

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005803·76 enrolled

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00907036·49 enrolled

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00387959·17 enrolled

Show 11 more trials

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT04074746·45 enrolled

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Completed·—·Phase 1·NCT00182650·5 enrolled

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00119392·42 enrolled

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Withdrawn·NNational Institutes of Health Clinical Center (CC)·N/A·NCT00389506

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003204·515 enrolled

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00079443·60 enrolled

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00574496·25 enrolled

Fludara (Oral) Phase II Study for Indolent Lymphoma

Completed· Sanofi logo

Sanofi·Phase 2·NCT00688883·52 enrolled

Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00002779·34 enrolled

TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma

Completed·UUniversity of Wisconsin, Madison·N/A·NCT02652468·11 enrolled

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Unknown status·MMilton S. Hershey Medical Center·Phase 1·NCT00006100

Metastatic Melanoma10 trials

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02500576·18 enrolled

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Completed·PProvidence Cancer Center, Earle A. Chiles Research Institute·Phase 1·NCT00091143·20 enrolled

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00085462·61 enrolled

Show 7 more trials

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1/2·NCT00062036·33 enrolled

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00509496·21 enrolled

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·—·Phase 2·NCT00085423·20 enrolled

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00079144

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00513604·158 enrolled

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00096382·34 enrolled

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00303836·58 enrolled

Acute Lymphoblastic Leukemia10 trials

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00860574·96 enrolled

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Recruiting·MMartin Schrappe·Phase 3·NCT03643276·5,000 enrolled

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Show 7 more trials

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01690520·163 enrolled

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Withdrawn·JJuventas Cell Therapy Ltd.·Phase 1/2·NCT06009107

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT00589316·26 enrolled

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Crohn's Allogeneic Transplant Study

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01570348·2 enrolled

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00988715·17 enrolled

Combination Chemotherapy and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00027547

62 more indications

Kidney Cancer8 trials

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Completed·UUNICANCER·Phase 2·NCT00056095·57 enrolled

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005851·11 enrolled

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00078858·37 enrolled

Show 5 more trials

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00027573·36 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Withdrawn·FFox Chase Cancer Center·Phase 2·NCT00025519

Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer

Completed·UUniversity of Rochester·Phase 2·NCT00262886·35 enrolled

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Withdrawn·NNorthwestern University·Phase 1·NCT00006126

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Completed·FFred Hutchinson Cancer Center·N/A·NCT00005799·55 enrolled

Hematologic Malignancies8 trials

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT01118013·6 enrolled

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT06343376·1 enrolled

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT01028716·46 enrolled

Show 5 more trials

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·—·Phase 1·NCT02129582·14 enrolled

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Completed·FFred Hutchinson Cancer Center·N/A·NCT00014235·160 enrolled

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed·RRoswell Park Cancer Institute·Phase 2·NCT01529827·94 enrolled

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Completed·NNohla Therapeutics, Inc.·Phase 2·NCT01175785·15 enrolled

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Withdrawn·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT01652014

Myelodysplastic Syndrome7 trials

Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Unknown status·FFred Hutchinson Cancer Center·Phase 2·NCT01894477·102 enrolled

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02649764·15 enrolled

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03813147·12 enrolled

Show 4 more trials

Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

Completed·—·Phase 1·NCT02446964·31 enrolled

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02250937·116 enrolled

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00119366·18 enrolled

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00077558

Acute Myeloid Leukemia6 trials

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01787474·30 enrolled

Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Completed·CChildren's Oncology Group·Phase 1/2·NCT02642965·38 enrolled

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00070135·121 enrolled

Show 3 more trials

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00101140

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Completed·MMedical Research Council·Phase 3·NCT00005863

Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00045435·17 enrolled

Leukemia6 trials

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Terminated·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00066417·51 enrolled

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Withdrawn·CChildren's Oncology Group·Phase 1/2·NCT05320380

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Completed· Roche logo

Roche·Phase 3·NCT00281918·817 enrolled

Show 3 more trials

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Completed·CCancer and Leukemia Group B·Phase 2·NCT00006252·47 enrolled

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

Completed·FFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium·Phase 2·NCT00031655·30 enrolled

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Graft Versus Host Disease4 trials

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT03192397·35 enrolled

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Completed·—·Phase 2·NCT00589563·32 enrolled

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Show 1 more trial

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT01231412·174 enrolled

Multiple Myeloma4 trials

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00028600·60 enrolled

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00054353·16 enrolled

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00793572·32 enrolled

Show 1 more trial

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT01534143·1 enrolled

Breast Cancer4 trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer

Terminated·UUniversity of California, San Diego·Phase 2·NCT00074269·5 enrolled

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00365287·148 enrolled

Allogeneic Transplantation Using Mini-Conditioning for Treatment of Stage IV Breast Cancer

Withdrawn·—·Phase 2·NCT00006261

Show 1 more trial

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020176

Hematologic Cancer3 trials

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00723099·73 enrolled

Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00963872·31 enrolled

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00301951·7 enrolled

Bone Marrow Transplant3 trials

Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134004·210 enrolled

Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00028730·25 enrolled

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00789776·41 enrolled

Chronic Myelogenous Leukemia3 trials

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT01640301·47 enrolled

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00305708·40 enrolled

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027924

Lymphoid Malignancies2 trials

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01664910·27 enrolled

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02529813·26 enrolled

Myeloid Leukemia2 trials

Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT00004878

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003145·18 enrolled

Aplastic Anemia2 trials

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Unknown status·UUniversity of California, San Francisco·N/A·NCT00295997·35 enrolled

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2/3·NCT00003816·361 enrolled

Fanconi Anemia2 trials

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00453388·6 enrolled

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00093743·2 enrolled

Bone Marrow Transplantation2 trials

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Completed·UUnknown Sponsor·Phase 2/3·NCT00004255

Mantle Cell Lymphoma2 trials

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Completed·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT00053092·82 enrolled

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00058227·37 enrolled

Prevention2 trials

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Recruiting·MMarcela V. Maus, M.D.,Ph.D.·Phase 2·NCT06550141·28 enrolled

Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00914940·41 enrolled

Stem Cell2 trials

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01858740·20 enrolled

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02220985·84 enrolled

Immunodeficiency2 trials

Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00553098·29 enrolled

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00358657·14 enrolled

Relapsed or Refractory2 trials

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00871689·2 enrolled

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recruiting·SSumithira Vasu·Phase 1·NCT05418088·54 enrolled

Efficacy and Safety2 trials

Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL

Completed· Sanofi logo

Sanofi·Phase 2·NCT00311129·41 enrolled

Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL

Completed· Sanofi logo

Sanofi·Phase 2·NCT00185445·62 enrolled

Myelofibrosis2 trials

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Completed·—·Phase 1·NCT02917096·18 enrolled

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT02251821·61 enrolled

Myelodysplastic Syndromes2 trials

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·FFred Hutchinson Cancer Center·Phase 1·NCT00008177·79 enrolled

Immunotherapy1 trial

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT01145209·32 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT00448357·54 enrolled

Melanoma1 trial

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Recruiting·AAnusha Kalbasi·Phase 1·NCT04119024·18 enrolled

Myeloid Neoplasm1 trial

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Completed·UUniversity of Washington·Phase 2·NCT02756572·30 enrolled

Angioimmunoblastic T-Cell Lymphoma1 trial

Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00958854·37 enrolled

Relapsed/Refractory AML1 trial

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Completed·—·Phase 2·NCT00053287·42 enrolled

Recurrent or Metastatic1 trial

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Completed·—·N/A·NCT00521430·30 enrolled

Ovarian Cancer1 trial

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated·IInge Marie Svane·Phase 1/2·NCT04611126·6 enrolled

Relapsed or Refractory Hematologic Malignancies1 trial

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Completed·—·Phase 1·NCT01658319·20 enrolled

Hematological Diseases1 trial

Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases

Completed·WWake Forest University Health Sciences·Phase 2·NCT02248597·27 enrolled

Myeloproliferative Disorder1 trial

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00397813·77 enrolled

Cancer1 trial

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00796068·130 enrolled

Autoimmune Disorders1 trial

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT06434363·47 enrolled

Metastatic Cancer1 trial

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00670748·45 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00025038·100 enrolled

Prostate Cancer1 trial

PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·—·Phase 1·NCT03873805·14 enrolled

Advanced1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00719849·13 enrolled

Donor1 trial

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT01598025·3 enrolled

Colorectal Cancer1 trial

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT05040568·15 enrolled

Bone Marrow Failure Syndrome1 trial

Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

Completed·UUniversity of California, San Francisco·Phase 1·NCT00295971·21 enrolled

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00040846·60 enrolled

Hematopoietic Stem Cell Transplant1 trial

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·N/A·NCT01652092·57 enrolled

Langerhans Cell Histiocytosis1 trial

Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00618540·1 enrolled

Encephalopathy1 trial

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT04205838·23 enrolled

Peripheral Blood Stem Cell Transplantation1 trial

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03602898

Myeloid Malignancies1 trial

Off-the-shelf NK Cells + SCT for Myeloid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT05115630·24 enrolled

Locally Advanced1 trial

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT02070406·4 enrolled

Advanced Malignancies1 trial

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT01697527·6 enrolled

Pembrolizumab1 trial

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Withdrawn·RRoswell Park Cancer Institute·Phase 2·NCT03935347

Trial1 trial

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Completed·CCancer Trials Ireland·Phase 2·NCT00812669·52 enrolled

Blood Disease1 trial

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT00450983·1 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Completed·GGeoVax, Inc.·Phase 1/2·NCT03754933·10 enrolled

Genetic Disorder1 trial

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00008307·52 enrolled

Patients With Advanced Solid Tumors1 trial

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06066424·54 enrolled

Systemic Sclerosis1 trial

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00622895·3 enrolled

Acute Graft Versus Host Disease1 trial

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00105001·210 enrolled

Sources

References

[1]
ClinicalTrials.gov — 386 trial records for Fludarabine Phosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine Phosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine Phosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Fludara

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Stem Cell Transplant26 trials

Chronic Lymphocytic Leukemia20 trials

Lymphoma14 trials

Metastatic Melanoma10 trials

Acute Lymphoblastic Leukemia10 trials

Kidney Cancer8 trials

Hematologic Malignancies8 trials

Myelodysplastic Syndrome7 trials

Acute Myeloid Leukemia6 trials

Leukemia6 trials

Graft Versus Host Disease4 trials

Multiple Myeloma4 trials

Breast Cancer4 trials

Hematologic Cancer3 trials

Bone Marrow Transplant3 trials

Chronic Myelogenous Leukemia3 trials

Lymphoid Malignancies2 trials

Myeloid Leukemia2 trials

Aplastic Anemia2 trials

Fanconi Anemia2 trials

Bone Marrow Transplantation2 trials

Mantle Cell Lymphoma2 trials

Prevention2 trials

Stem Cell2 trials

Immunodeficiency2 trials

Relapsed or Refractory2 trials

Efficacy and Safety2 trials

Myelofibrosis2 trials

Myelodysplastic Syndromes2 trials

Immunotherapy1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Melanoma1 trial

Myeloid Neoplasm1 trial

Angioimmunoblastic T-Cell Lymphoma1 trial

Relapsed/Refractory AML1 trial

Recurrent or Metastatic1 trial

Ovarian Cancer1 trial

Relapsed or Refractory Hematologic Malignancies1 trial

Hematological Diseases1 trial

Myeloproliferative Disorder1 trial

Cancer1 trial

Autoimmune Disorders1 trial

Metastatic Cancer1 trial

Juvenile Myelomonocytic Leukemia1 trial

Prostate Cancer1 trial

Advanced1 trial

Donor1 trial

Colorectal Cancer1 trial

Bone Marrow Failure Syndrome1 trial

AML1 trial

Epidermolysis Bullosa1 trial

Hematological Malignancies1 trial

Hematopoietic Stem Cell Transplant1 trial

Langerhans Cell Histiocytosis1 trial

Encephalopathy1 trial

Peripheral Blood Stem Cell Transplantation1 trial

Myeloid Malignancies1 trial

Locally Advanced1 trial

Advanced Malignancies1 trial

Pembrolizumab1 trial

Trial1 trial

Blood Disease1 trial

Safety and Efficacy1 trial

Genetic Disorder1 trial

Patients With Advanced Solid Tumors1 trial

Systemic Sclerosis1 trial

Acute Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News